Study for the affect of in the endoscopic minimally invasive treatment of esophagus submucous protrusion lesion

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900027975

Enrollment

Unknown

Registered

2019-12-07

Start date

2019-12-10

Completion date

Unknown

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophagus submucous protrusion lesion

Interventions

Group 2:Endoscopic minimally invasive treatment

Group 1:Endoscopic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Willing to comply with the study procedures, signed the informed consent with clear consciousness; 2. Between 18 to 70 years of age; 3. Endoscopic ultrasonography (EUS) in the diagnoses of esophagus submucous protrusion lesion (esophageal leiomyoma?) with diameter between 0.5 cm to 1 cm.

Exclusion criteria

Exclusion criteria: 1. With serious cardiovascular, renal or liver disease, such as severe pulmonary or renal insufficiency, cannot tolerate endoscopic minimally invasive treatment; 2. Pregnant stage and breast - feed stage; 3. Have a mental disorder or disease, conscious behavior ability partially or completely restricted, no independent decision ability; 4. Cannot understand Chinese characters; 5. Participated in other clinical trials,or had in other clinical trial within 60 days; 6. Refused to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
SF-36;HADS;	—

Countries

China

Contacts

Public ContactWang Chong

Department of Gastroenterology, The First Affiliated Hospital of Nanchang University

wangchyx@163.com+86 13732908582

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026